Venlafaxine updated on 07-01-2025

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18311
R77110		 Martin, 2024 Preterm delivery (delivery at <259 days (37 weeks’)) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.74 [1.60;1.91] 679/6,441   119,950/2,408,707 120,629 6,441
ref
S13135
R50111		 Marks (Controls exposed to Bupropion), 2021 Preterm Birth during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.89 [0.51;1.57] C 18/132   61/406 79 132
ref
S11775
R43321		 Richardson, 2019 Preterm birth at least 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: Yes Matched Monotherapy: no or not specified 1.51 [0.98;2.27] 33/198   125/1,081 158 198
ref
S11792
R43392		 Ozturk, 2016 Preterm Births (<37 weeks) at least 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 1.33 [0.07;24.63] C 0/11   8/246 8 11
ref
S11777
R43339		 Te Winkel, 2016 Preterm deliveries during pregnancy (anytime or not specified) prospective cohort unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 2.02 [1.32;3.10] C 62/590   36/656 98 590
ref
S13353
R51473		 Calderon-Margalit, 2009 Preterm delivery (before 37 weeks of gestation) during pregnancy (anytime or not specified) prospective cohort unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 3.78 [0.81;17.60] 4/9   234/2,493 238 9
ref
Total 6 studies 1.64 [1.33;2.02] 121,210 7,381
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Martin, 2024Martin, 2024 1.74[1.60; 1.91]120,6296,44152%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Marks (Controls exposed to Bupropion), 2021Marks, 2021 1 0.89[0.51; 1.57]7913211%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Richardson, 2019Richardson, 2019 1.51[0.98; 2.27]15819818%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Ozturk, 2016Ozturk, 2016 1.33[0.07; 24.63]8111%ROB confusion: criticalROB selection: unclearROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Te Winkel, 2016Te Winkel, 2016 2.02[1.32; 3.10]9859017%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: unclearROB reporting: moderate Calderon-Margalit, 2009Calderon-Margalit, 2009 3.78[0.81; 17.60]23892%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (6 studies) I2 = 30% 1.64[1.33; 2.02]121,2107,3810.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls exposed to Bupropion;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.64[1.33; 2.02]121,2107,38130%NAMartin, 2024 Marks (Controls exposed to Bupropion), 2021 Richardson, 2019 Ozturk, 2016 Te Winkel, 2016 Calderon-Margalit, 2009 6 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.74[1.60; 1.90]121,1317,2490%NAMartin, 2024 Richardson, 2019 Ozturk, 2016 Te Winkel, 2016 Calderon-Margalit, 2009 5 exposed to other treatment, sickexposed to other treatment, sick 0.89[0.51; 1.57]79132 -NAMarks (Controls exposed to Bupropion), 2021 1 Tags Adjustment   - No  - No 1.38[0.69; 2.74]18573361%NAMarks (Controls exposed to Bupropion), 2021 Ozturk, 2016 Te Winkel, 2016 3   - Yes  - Yes 1.73[1.59; 1.89]121,0256,6480%NAMartin, 2024 Richardson, 2019 Calderon-Margalit, 2009 3 MatchedMatched 1.51[0.99; 2.30]158198 -NARichardson, 2019 1 Monotherapy   - no or not specified  - no or not specified 1.79[1.33; 2.40]5028080%NARichardson, 2019 Ozturk, 2016 Te Winkel, 2016 Calderon-Margalit, 2009 4   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.33[0.70; 2.52]120,7086,57381%NAMartin, 2024 Marks (Controls exposed to Bupropion), 2021 2 All studiesAll studies 1.64[1.33; 2.02]121,2107,38130%NAMartin, 2024 Marks (Controls exposed to Bupropion), 2021 Richardson, 2019 Ozturk, 2016 Te Winkel, 2016 Calderon-Margalit, 2009 60.210.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.54.01.7870.000Martin, 2024Marks (Controls exposed to Bupropion), 2021Richardson, 2019Ozturk, 2016Te Winkel, 2016Calderon-Margalit, 2009

Asymetry test p-value = 0.7010 (by Egger's regression)

slope=0.5609 (0.0731); intercept=-0.2881 (0.6979); t=0.4127; p=0.7010

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.74[1.60; 1.90]121,1317,2490%NAMartin, 2024 Richardson, 2019 Ozturk, 2016 Te Winkel, 2016 Calderon-Margalit, 2009 5 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.89[0.51; 1.57]79132 -NAMarks (Controls exposed to Bupropion), 2021 10.510.01.0